Vor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million - VOR News | RalliesVor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million
V
VOR• Q2 FY26 results
- Vor Bio posted a Q2 2026 net loss of $62.8 million, narrowing from $1.57 billion a year earlier.
- R&D expenses fell 90.1% to $25.9 million, driven by the prior-year Telitacicept License Agreement charge and restructuring-related costs.
- G&A expenses rose 71.1% to $21.9 million on higher stock-based compensation, personnel, and commercial-related spending.
Cash position and clinical programs
- Cash, cash equivalents, and marketable securities totaled $466.1 million at June 30, 2026; pro forma cash and investments were $514.5 million.
- Phase 3 UPSTREAM MG enrollment remains on track, with topline data expected in 1H27.
- UPSTREAM SjD enrollment continues, with new China approvals in SjD and IgAN.
